Results 41 to 50 of about 4,575,740 (255)

Mutant p53 and ETS2, a tale of reciprocity

Frontiers in Oncology, 2016
TP53 is one of the most frequently inactivated tumor suppressor genes in human cancer. However, unlike other tumor suppressor genes whose expression is lost, TP53 is usually inactivated as a result of a single nucleotide change within the coding region.
Luis Alfonso Martinez
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

The human adenovirus 5 L4 promoter is activated by cellular stress response protein p53 [PDF]

, 2013
During adenovirus infection, the emphasis of gene expression switches from early genes to late genes in a highly regulated manner. Two gene products, L4-22K and L4-33K, contribute to this switch by activating the Major Late Transcription Unit (MLTU) and ...
Leppard, Keith, Wright, Jordan
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Novel p53 therapies for head and neck cancer

World Journal of Otorhinolaryngology-Head and Neck Surgery, 2016
Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of ...
Mario R. Castellanos, Quintin Pan
doaj   +1 more source

Progress of TP53 Family Gene TP73 and Tumorigenesis

Zhongliu Fangzhi Yanjiu, 2021
P73 protein is one of the main members of p53 protein family, and its coding gene TP73 is highly homologous to TP53 gene. On one hand, similar to p53, p73 protein is involved in all aspects of cell life.
XU Jie, HAO Mu
doaj   +1 more source

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis [PDF]

, 2013
The role of apoptosis in melanoma pathogenesis and chemoresistance is poorly characterized. Mutations in TP53 occur infrequently, yet the TP53 apoptotic pathway is often abrogated.
Graf, M, Mesher, D, Francesca Moretti, Chiorino, G, A. Chikh, Costanzo, A, M. Graf, D. Bergamaschi, Leigh, IM, Cerio, R, Maria Scatolini, Chong, SLP, C. M. Proby, Anissa Chikh, Antonio Costanzo, Matin, RN, Moretti, F, COSTANZO, ANTONIO, Charlotte M. Proby, Valentina Senatore, C. A. Harwood, Senatore, V, I. M. Leigh, D. Mesher, Harwood, CA, Catherine A. Harwood, R. N. Matin, Stephanie Law Pak Chong, Paolo Sanza’, Rino Cerio, R. Cerio, Bergamaschi, D, David Mesher, P. Sanza', M. Scatolini, Irene M. Leigh, S. L. Pak, Rubeta N. Matin, Proby, CM, V. Senatore, Daniele Bergamaschi, F. Moretti, Chikh, A, Sanza', P, Scatolini, M, Giovanna Chiorino, G. Chiorino, Manuela Graf   +47 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

p66α Suppresses Breast Cancer Cell Growth and Migration by Acting as Co-Activator of p53

Cells, 2021
p66α is a GATA zinc finger domain-containing transcription factor that has been shown to be essential for gene silencing by participating in the NuRD complex. Several studies have suggested that p66α is a risk gene for a wide spectrum of diseases such as
Qun Zhang, Yihong Zhang, Jie Zhang, Dan Zhang, Mengying Li, Han Yan, Hui Zhang, Liwei Song, Jiamin Wang, Zhaoyuan Hou, Yunhai Yang, Xiuqun Zou   +11 more
doaj   +1 more source